Cidara Therapeutics (CDTX) announced it presented late-breaking Phase 2b clinical data on its non-vaccine influenza preventative candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. Summary: CD388’s safety and prevention efficacy against influenza A and B in healthy, unvaccinated adults were evaluated in a double-blind, randomized, placebo-controlled, Phase 2b study. Each CD388 dose tested provided significant PE versus placebo: 57.7%, 61.3%, and 76.1%. CD388 was well tolerated with no apparent safety issues. The results suggested that a single dose of CD388 could have the potential to provide season-long prevention of influenza illness in individuals not adequately protected by available influenza vaccines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics initiated with an Overweight at Morgan Stanley
- Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Cidara Therapeutics initiated with an Overweight at JPMorgan
- Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating